P

    Precision BioSciences Inc (DTIL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.64
    -0.14 (-1.80%)

    Market Cap: $214.74M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(23/30)
    Avg Surprise
    -62.00%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.89
    Range$-1.19 - $-0.63
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.61+31.5%
    60d ago$-0.65+27.3%
    30d ago$-0.65+27.3%
    7d ago$-0.85+4.1%
    Current$-0.89
    Revenue Consensus
    $1M
    Range$0 - $3M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-1.47
    Range$-2.04 - $-0.64
    3 analysts
    Revenue Consensus
    $7M
    Range$5M - $10M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.47---
    Sep 26EST
    		-$-0.89---
    Jun 26
    		$-0.71$-0.74+4.05%Beat+66.7%
    Mar 26
    		$-0.75$-0.81+7.41%Beat+66.1%
    Dec 25
    		$1.01$-0.64+256.37%Beat+147.1%
    Sep 25
    		$-1.84$-2.21+16.74%Beat+18.2%
    Jun 25
    		$-2.13$-0.09-2266.67%Miss-145.6%
    Mar 25
    		$-2.21$-0.43-413.95%Miss-230.0%
    Dec 24
    		$-2.14$-2.94+27.47%Beat+47.4%
    Sep 24
    		$-2.25$-3.13+28.11%Beat-7.1%
    Jun 24
    		$4.67$-5.07+192.11%Beat+255.7%
    Mar 24
    		$1.70$-1.91+189.01%Beat+126.0%
    Dec 23
    		$-4.06$-2.05-98.05%Miss-1461.5%
    Sep 23
    		$-2.10N/A+58.00%Beat+68.2%
    Jun 23
    		$-3.00N/A+60.00%Beat+78.3%
    Mar 23
    		$-6.55$-6.60+0.76%Beat+52.5%
    Dec 22
    		$-0.26$-0.21-23.81%Miss+50.0%
    Sep 22
    		$-6.60$-11.16+40.86%Beat-13.4%
    Jun 22
    		$-13.80$-13.92+0.86%Beat-227.8%
    Mar 22
    		$-13.80$-16.20+14.81%Beat-39.4%
    Dec 21
    		$-0.52$-0.47-10.64%Miss-18.2%
    Sep 21
    		$-5.82N/A+67.14%Beat+61.2%
    Jun 21
    		$10.80$-17.07+163.27%Beat+157.1%
    Mar 21
    		$-9.90$-16.47+39.89%Beat+36.5%
    Dec 20
    		$-0.44$-0.11-300.00%Miss-22.2%
    Sep 20
    		$-15.00$-20.33+26.22%Beat-22.0%
    Jun 20
    		$-18.90$-18.26-3.50%Miss-91.1%
    Mar 20
    		$-15.60$-16.00+2.50%Beat-36.8%
    Dec 19
    		$-0.36$-0.48+25.00%Beat-
    Sep 19
    		$-12.30$-13.58+9.43%Beat-8100.0%
    Jun 19
    		$-9.89$-12.98+23.81%Beat-
    Mar 19
    		$-11.40$-11.72+2.73%Beat-
    Dec 18
    		$0.00$0.00N/ABeat-
    Sep 18
    		$-0.15$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.33EV/EBITDA-0.27x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-117.00%Operating Margin-80.80%
    ROE-135.10%ROIC3.82%
    Financial Health
    Debt/Equity0.50xInterest Coverage1.84x
    Current Ratio12.82xQuick Ratio12.82x
    Trading Statistics
    Beta1.23Avg Volume287.79K
    52-Week High$9.6252-Week Low$3.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.36
    SMA 20$7.89
    SMA 50$7.81
    SMA 200$6.12
    EMA 10$8.10
    EMA 20$7.97
    EMA 50$7.71
    EMA 200$6.63

    MACD

    Line: 0.17Signal: 0.19Hist: -0.02

    ADX

    ADX: 19.0+DI: 22.1-DI: 23.5

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down8.0
    PSAR$9.25

    Bollinger Bands

    Upper Band$9.00
    Lower Band$6.78
    %B Position2806%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    45.2

    Momentum Oscillators

    Stoch %K35.2
    Stoch %D48.2
    Williams %R-78.7
    ROC (10d)3.2%
    Momentum0.24
    CCI (20d)-34.2
    MFI (14d)45.8

    Volatility Measures

    ATR (14d)$0.47(6.2%)
    StdDev (20d)0.55
    Hist Vol57.4%(High)

    Volume Flow

    VWAP$7.64
    OBV6.8M
    AD Line-2.1M
    CMF (20d)-0.114

    Volume Metrics

    Avg Vol (20d)287.8K
    Vol Ratio0.7x
    VWMA (20d)$7.97

    Pivot Points

    R3$8.94
    R2$8.69
    R1$8.23
    Pivot Point$7.98
    S1$7.52
    S2$7.27
    S3$6.81

    Advanced Oscillators

    TSI12.31
    Ultimate Osc38.9
    KST76.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$10.84M$34.20M$13,000$18,000$29,000$638,000$576,000$49.90M$17.58M$7.04M$13.12M
    Cost of Revenue$0$0$678,000$0$0$0$757,000$0$0$0$1.56M$0
    Gross Profit$0$10.84M$34.20M$13,000$18,000$29,000$638,000$576,000$49.90M$17.58M$7.04M$13.12M
    Operating Expenses$19.16M$19.91M$22.13M$20.68M$21.92M$22.15M$25.30M$21.85M$25.94M$21.77M$21.92M$25.48M
    R&D$12.39M$13.11M$14.46M$13.35M$12.77M$13.59M$15.91M$13.08M$17.23M$13.34M$13.39M$15.85M
    SG&A$6.77M$6.80M$7.23M$7.33M$9.13M$8.55M$9.58M$8.77M$8.53M$8.43M$8.54M$9.63M
    Operating Income$-19,161,000$-9,075,000$12.51M$-20,667,000$-21,877,000$-22,112,000$-24,846,000$-21,275,000$24.15M$-4,187,000$-14,890,000$-12,363,000
    Interest Income$943,000$999,000$-4,597,000$436,000$451,000$2.67M$522,000$888,000$893,000$3.38M$956,000$520,000
    Interest Expense$300,000$311,000$348,000$362,000$358,000$354,000$392,000$256,000$560,000$574,000$579,000$576,000
    Income Before Tax$-32,653,000$-18,445,000$19.68M$-21,775,000$-23,495,000$-20,556,000$-17,934,000$-16,425,000$32.94M$8.59M$-13,443,000$-12,108,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-32,652,000$-18,441,000$20.13M$-21,772,000$-23,520,000$-20,565,000$-17,745,000$-16,425,000$32.75M$8.59M$-16,289,000$-8,079,000
    EBITDA$-32,695,000$-18,376,000$25.33M$-21,388,000$-23,056,000$-22,303,000$-17,475,000$-16,299,000$33.85M$7.33M$-12,413,000$-10,088,000
    EBIT$-33,296,000$-19,133,000$24.63M$-21,849,000$-23,588,000$-22,867,000$-18,064,000$-17,057,000$32.60M$5.79M$-13,820,000$-12,052,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DTIL

    News

    Precision BioSciences (DTIL) draws 1.1M-share Weinstein stake

    Benjamin Weinstein has reported a 4.01% stake in Precision BioSciences (DTIL), holding 1,105,720 shares, which includes 203,500 shares from warrants. This beneficial ownership is based on 27,601,554 shares outstanding as of August 3, 2026. Weinstein confirms sole and shared voting and dispositive power over these shares, indicating a passive investment below the 5% threshold.

    Stock Titan•8/24/26•
    Neutral

    DTIL Looks 373.3% Overvalued on GF Value™

    Precision BioSciences Inc (NASDAQ: DTIL) has initiated dosing in its Phase 1/2 FUNCTION-DMD clinical trial, a significant milestone for its gene editing therapy for Duchenne muscular dystrophy. Despite this clinical progress, the company appears substantially overvalued, with its stock trading 373.3% above its GF Value™ and a Price-to-Sales ratio slightly exceeding its historical median, reflecting expectations of future revenue growth while the company remains unprofitable. Insider and guru activity shows net selling and trimmed positions, suggesting cautious sentiment among informed investors.

    GuruFocus•8/24/26•
    Somewhat-Bearish

    Precision BioSciences doses first patient in DMD gene editing trial By Investing.com

    Precision BioSciences has dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial, evaluating PBGENE-DMD for Duchenne muscular dystrophy. The gene editing therapy aims to restore functional dystrophin protein in up to 60% of DMD patients. Initial safety data is expected by year-end 2026 for the trial, which is enrolling ambulatory patients aged 2 to 7.

    Investing.com Nigeria•8/24/26•
    Bullish

    Precision BioSciences starts PBGENE-DMD gene editing trial

    Precision BioSciences has initiated its Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. The trial has dosed its first patient and is recruiting ambulatory DMD patients aged 2-7 with specific genetic mutations. Initial safety data from the study is anticipated by the end of 2026.

    grafa.com•8/24/26•
    Bullish

    Precision BioSciences doses first patient in DMD gene editing trial

    Precision BioSciences has dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy. The therapy aims to restore near full-length functional dystrophin protein by excising specific exons, a method applicable to up to 60% of DMD patients. The company anticipates releasing initial safety data by the end of 2026.

    Investing.com•8/24/26•
    Bullish

    Frequently Asked Questions About DTIL

    Does DTIL pay dividends?
    Precision BioSciences Inc (DTIL) does not currently pay a regular dividend.
    What is DTIL's market cap?
    Precision BioSciences Inc (DTIL) has a market capitalization of $214.74M with a current stock price of $7.64.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In